MCID: RTN020
MIFTS: 46

Retinal Vascular Disease

Categories: Cardiovascular diseases, Eye diseases, Neuronal diseases

Aliases & Classifications for Retinal Vascular Disease

MalaCards integrated aliases for Retinal Vascular Disease:

Name: Retinal Vascular Disease 12 15
Retinal Vascular 54 71
Retina Circulation Disorder 12
Retinal Vascular Disorder 71

Classifications:



External Ids:

Disease Ontology 12 DOID:2462
NCIt 49 C35170
SNOMED-CT 67 57534004
UMLS 71 C0154833 C0549652

Summaries for Retinal Vascular Disease

MalaCards based summary : Retinal Vascular Disease, also known as retinal vascular, is related to vascular disease and retinal vein occlusion, and has symptoms including chest pain An important gene associated with Retinal Vascular Disease is VEGFA (Vascular Endothelial Growth Factor A), and among its related pathways/superpathways are Folate Metabolism and MicroRNAs in cancer. The drugs Ketorolac and Zinc have been mentioned in the context of this disorder. Affiliated tissues include endothelial, retina and eye, and related phenotypes are liver/biliary system and vision/eye

Related Diseases for Retinal Vascular Disease

Diseases related to Retinal Vascular Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 533)
# Related Disease Score Top Affiliating Genes
1 vascular disease 31.9 VEGFA PLG MTHFR MIR21 MIR126 KDR
2 retinal vein occlusion 31.8 VEGFA SERPINF1 MTHFR KDR
3 central retinal vein occlusion 31.3 VEGFA SERPINF1 PLG MTHFR
4 intraocular pressure quantitative trait locus 31.3 VEGFA SERPINF1 CRYAA CCN2
5 branch retinal artery occlusion 31.3 VEGFA PLG MTHFR CRYAA
6 microvascular complications of diabetes 1 31.2 VEGFA SERPINF1 INS CCN2 AKR1B1
7 macular retinal edema 31.2 VEGFA SERPINF1 KDR INS CRYAA ALB
8 retinal artery occlusion 31.2 VEGFA PLG MTHFR KDR CRYAA
9 kuhnt-junius degeneration 31.2 VEGFA PLG MIR126 KDR CRYAA
10 macular degeneration, age-related, 1 31.2 VEGFA SERPINF1 PLG KDR INS H2AC18
11 atherosclerosis susceptibility 31.1 VEGFA MTHFR INS ALB
12 retinal disease 31.1 NDP H2AC18 CRYAA ALB AIPL1
13 diabetic macular edema 31.1 VEGFA SERPINF1 AKR1B1
14 lipid metabolism disorder 31.1 MIR21 MIR126 INS H2AC18
15 exudative vitreoretinopathy 1 31.0 VEGFA SERPINF1 NDP KDR CRYAA
16 hyperglycemia 31.0 MIR126 INS ALB AKR1B1
17 coats disease 31.0 VEGFA NDP KDR
18 background diabetic retinopathy 30.9 VEGFA KDR INS ALB AKR1B1
19 endophthalmitis 30.9 VEGFA PLG CRYAA ALB
20 retinal vascular occlusion 30.9 VEGFA SERPINF1 PLG MTHFR KDR CRYAA
21 diabetes mellitus 30.9 VEGFA MTHFR MIR20A MIR126 KDR INS
22 neovascular glaucoma 30.9 VEGFA PLG KDR CRYAA
23 corneal neovascularization 30.8 VEGFA SERPINF1 PLG KDR CRYAA
24 retinal detachment 30.8 VEGFA SERPINF1 NDP CCN2
25 rubeosis iridis 30.8 VEGFA PLG
26 macular holes 30.7 VEGFA SERPINF1 PLG CRYAA
27 pre-eclampsia 30.7 VEGFA MTHFR MIR126 KDR INS ALB
28 diabetic neuropathy 30.7 VEGFA INS AKR1B1
29 retinal microaneurysm 30.7 VEGFA MIR20A INS AKR1B1
30 muscular dystrophy 30.7 VEGFA LIF KDR INS CCN2 ALB
31 central retinal artery occlusion 30.7 VEGFA PLG MTHFR CRYAA
32 leukostasis 30.7 VEGFA SERPINF1 KDR
33 cataract 30.6 VEGFA SERPINF1 MTHFR INS CRYAA ALB
34 polyneuropathy 30.6 VEGFA INS ALB AKR1B1
35 microvascular complications of diabetes 5 30.6 VEGFA SERPINF1 PLG MIR30A MIR21 MIR20B
36 telangiectasis 30.6 VEGFA NDP H2AC18
37 impotence 30.6 VEGFA INS ALB
38 fundus dystrophy 30.6 VEGFA SERPINF1 KDR INS CRYAA ALB
39 non-alcoholic fatty liver disease 30.6 MIR30A MIR21 MIR126 INS ALB
40 macular dystrophy, dominant cystoid 30.6 VEGFA SERPINF1 CRYAA
41 retinitis pigmentosa 30.5 VEGFA SERPINF1 LIF INS H2AC18 CRYAA
42 hypertension, essential 30.5 VEGFA PLG MTHFR MIR30A MIR21 MIR126
43 eclampsia 30.5 VEGFA MTHFR ALB
44 lipoprotein quantitative trait locus 30.5 VEGFA PLG MIR21 MIR126 KDR ALB
45 chronic kidney disease 30.5 VEGFA MTHFR INS CCN2 ALB
46 placenta disease 30.5 VEGFA MTHFR INS H2AC18
47 vitreoretinopathy, neovascular inflammatory 30.5 VEGFA CRYAA CCN2
48 apnea, obstructive sleep 30.5 VEGFA INS ALB
49 atrial fibrillation 30.4 MIR21 MIR126 INS ALB
50 migraine with or without aura 1 30.4 PLG MTHFR INS H2AC18 ALB

Graphical network of the top 20 diseases related to Retinal Vascular Disease:



Diseases related to Retinal Vascular Disease

Symptoms & Phenotypes for Retinal Vascular Disease

UMLS symptoms related to Retinal Vascular Disease:


chest pain

MGI Mouse Phenotypes related to Retinal Vascular Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 liver/biliary system MP:0005370 9.56 ALB CCN2 INS KDR LIF MTHFR
2 vision/eye MP:0005391 9.36 AIPL1 AKR1B1 CCN2 INS KDR LIF

Drugs & Therapeutics for Retinal Vascular Disease

Drugs for Retinal Vascular Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 112)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ketorolac Approved Phase 4 66635-83-4, 74103-06-3 3826
2
Zinc Approved, Investigational Phase 4 7440-66-6 32051
3
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
4
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
5
Copper Approved, Investigational Phase 4 7440-50-8 27099
6
Travoprost Approved Phase 4 157283-68-6 5282226
7
tannic acid Approved Phase 4 1401-55-4
8
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
9
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
10
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
11
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 68-26-8, 11103-57-4 9904001 445354
12 Tocotrienol Investigational Phase 4 6829-55-6
13 Analgesics, Non-Narcotic Phase 4
14 Analgesics Phase 4
15 Anti-Inflammatory Agents, Non-Steroidal Phase 4
16 Ketorolac Tromethamine Phase 4
17 Cyclooxygenase Inhibitors Phase 4
18 Mitogens Phase 4
19 Endothelial Growth Factors Phase 4
20 Vitamins Phase 4
21 Tocopherols Phase 4
22 Tocotrienols Phase 4
23 Copper Supplement Phase 4
24 retinol Phase 4
25 Antioxidants Phase 4
26 Retinol palmitate Phase 4
27 Vasodilator Agents Phase 4
28 Hormones Phase 4
29 Hemostatics Phase 4
30 Coagulants Phase 4
31 Calcium, Dietary Phase 4
32 Calcium Dobesilate Phase 4
33
Calcium Nutraceutical Phase 4 7440-70-2 271
34
Ranibizumab Approved Phase 3 347396-82-1 459903
35
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
36
Bevacizumab Approved, Investigational Phase 3 216974-75-3
37
Infliximab Approved Phase 3 170277-31-3
38 Anti-Inflammatory Agents Phase 3
39 Hormone Antagonists Phase 3
40 glucocorticoids Phase 3
41 Triamcinolone diacetate Phase 3
42 Triamcinolone hexacetonide Phase 3
43 triamcinolone acetonide Phase 3
44 Immunologic Factors Phase 3
45 Immunosuppressive Agents Phase 3
46 Angiogenesis Inhibitors Phase 3
47 Antineoplastic Agents, Immunological Phase 3
48 Antirheumatic Agents Phase 3
49 Gastrointestinal Agents Phase 3
50 Dermatologic Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 135)
# Name Status NCT ID Phase Drugs
1 Peripheral and Macular Retinal Vascular Perfusion and Leakage Dynamics in Diabetic Macular Edema and Retinal Venous Occlusions During Intravitreal Aflibercept Injection (IAI) Treatment for Retinal Edema: PERMEATE Study Completed NCT02503540 Phase 4 Aflibercept
2 A Randomized, Masked Comparison of Topical Ketorolac 0,4% Versus Placebo in Cataract Surgery. Completed NCT01542190 Phase 4 Ketorolac Tromethamine
3 Effect of Antioxidants on Ocular Blood Flow, Endothelial Function, and Cytokine Levels in LPS Induced Inflammatory Model in Humans. Completed NCT00431691 Phase 4 vitamin and mineral supplement;Escherichia coli Endotoxin (LPS);100% O2;nitroglycerin
4 Open Label Macugen for the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion Completed NCT00406107 Phase 4 pegaptanib sodium (Macugen)
5 Influence of Travoprost 0.004% and Latanoprost 0.005% on Retinal Vascular Diameter and Choroidal Blood Flow in Glaucoma Patients Completed NCT00308945 Phase 4 travoprost 0.004% (drug);latanoprost 0.005% (drug)
6 Prospective Trial of Treat and Extend Aflibercept for Macular Edema Secondary to Branch Retinal Vein Occlusion: the PLATON Trial Recruiting NCT03405376 Phase 4 Intravitreal aflibercept injection
7 Efficacy of Calcium Dobesilate in Treating Chinese Patients With Mild to Moderate Non-proliferative Diabetic Retinopathy (CALM-DR): a Single-blind, Multicenter, Cluster-randomized, Controlled Trial Not yet recruiting NCT04283162 Phase 4 Calcium Dobesilate
8 Comparison of Timing and Image Quality of Different Phases of Optos Fluorescein Angiography Between Two Doses of Intravenous Fluorescein: 250mg Versus 500mg Suspended NCT03244982 Phase 4 Fluorescein Na 10% Inj 500mg;Fluorescein Na 10% Inj 250mg
9 Bevacizumab and Retinal Vascular Occlusions Unknown status NCT00347711 Phase 3 Intravitreal injection
10 Branch Vein Occlusion Study Completed NCT00000162 Phase 3
11 Central Vein Occlusion Study (CVOS) Completed NCT00000131 Phase 3
12 Treatment With Anti-vascular Endothelial Growth Factor in Patients With Branch Retinal Vein Occlusion: 5 Years of Clinical Experience Completed NCT02033031 Phase 3 Lucentis intravitreal injection;Avastin intravitreal injection
13 Intravitreal Bevacizumab and Intravitreal Triamcinolone Associated to Laser Photocoagulation for Diabetic Macular Edema(IBeTA) Completed NCT00997191 Phase 3 Intravitreal triamcinolone;Intravitreal bevacizumab
14 An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy Completed NCT00996437 Phase 2, Phase 3 Ranibizumab;Saline
15 Intravitreal Ranibizumab or Triamcinolone Acetonide in Combination With Laser Photocoagulation for Diabetic Macular Edema Completed NCT00444600 Phase 3 Triamcinolone Acetonide + laser;Ranibizumab + laser;Sham injection + laser;Ranibizumab + deferred laser
16 A Randomized Trial Comparing Intravitreal Triamcinolone Acetonide and Laser Photocoagulation for Diabetic Macular Edema Completed NCT00105404 Phase 3 Triamcinolone Acetonide
17 A Randomized Trial Comparing Intravitreal Triamcinolone Acetonide and Laser Photocoagulation for Diabetic Macular Edema Completed NCT00367133 Phase 3 1mg triamcinolone acetonide;4mg triamcinolone acetonide
18 Multicenter Randomized Controlled Trial on the Interest of Intravitreal Injections of Anti-VEGF as Initial and Adjuvant Treatment in Coats Disease Recruiting NCT03940690 Phase 3 Anti-VEGF injections of bevacizumab
19 Infliximab for Diabetic Macular Edema Refractory to Laser Photocoagulation: a Randomized, Double-Masked, Placebo-Controlled, Cross-Over, 32 Weeks Study Terminated NCT00505947 Phase 3 infliximab;placebo
20 Intravitreal Avastin Versus Intravitreal Avastin and Triamcinolone in Central Retinal Vein Occlusion(CRVO) Unknown status NCT00370630 Phase 2 Avastin (Bevacizumab) and triamcinolone
21 The Effect of A2A Adrenoceptor Stimulation on the Diameter of Retinal Arterioles During Hypoxia in Vivo Unknown status NCT03090087 Phase 2 Regadenoson
22 The Efficacy of Intravitreal Aflibercept Injection in Improvement of Retinal Nonperfusion in Patients With Diabetic Retinopathy Unknown status NCT03006081 Phase 2 Intravitreal Aflibercept injection
23 Vitamin D Supplementation in Polycystic Ovary Syndrome: a Randomized Controlled Trial. Completed NCT00907153 Phase 1, Phase 2 Placebo
24 Evaluation of the Pain and Visual Outcome Associated With Location of Intravitreal Bevacizumab Injection Completed NCT02790775 Phase 2 Anti-VEGF in quadrant 1;Anti-VEGF in quadrant 2;Anti-VEGF in quadrant 3;Anti-VEGF in quadrant 4
25 Determination of the rhIGF-1/rhIGFBP-3 Dose, Administered as a Continuous Infusion, Required to Establish and Maintain Longitudinal Serum IGF-1 Levels Within Physiological Levels in Premature Infants, to Prevent Retinopathy of Prematurity A Phase 2, Randomized Controlled, Assessor-blind, Dose Confirming, Pharmacokinetic, Safety and Efficacy, Multicenter Study Completed NCT01096784 Phase 2 rhIGF-I/rhIGFBP-3
26 Prospective, Randomized, Open Label, Phase II Study to Assess Efficacy and Safety of Macugen® (Pegaptanib 0.3 mg Intravitreal Injections) Plus Panretinal Photocoagulation (PRP) and PRP (Monotherapy) in the Treatment of Patients With High Risk Proliferative Diabetic Retinopathy (PDR). Completed NCT01281098 Phase 2 Intravitreous injection of pegaptanib
27 Prospective, Randomized, Multicenter, Open Label, Phase II Study to Access Efficacy and Safety of Lucentis® Monotherapy (Ranibizumab 0.5 mg Intravitreal Injections) Compared With Lucentis® Plus Panretinal Photocoagulation (PRP) and PRP (Monotherapy) in the Treatment of Patients With High Risk Proliferative Diabetic Retinopathy Completed NCT01280929 Phase 2 Intravitreous injection of ranibizumab
28 A Phase 2 Evaluation of Anti-VEGF Therapy for Diabetic Macular Edema: Bevacizumab (Avastin) Completed NCT00336323 Phase 2 Bevacizumab;Bevacizumab;Bevacizumab;Bevacizumab
29 A Pilot, Open-Label Study of the Safety, Tolerability, and Bioactivity of Multiple Intravitreal Injections of Ranibizumab in Subjects With Macular Edema Secondary to Vein Occlusions. Completed NCT00407355 Phase 1, Phase 2 Intravitreal injection of ranibizumab .3 dose;Intravitreal injection of Ranibizumab .5 dose
30 Daclizumab for Active, Non-infectious, Sight-threatening Uveitis: A Phase II Pilot Study Completed NCT00070759 Phase 2 Daclizumab
31 A Pilot Study of Peribulbar Triamcinolone Acetonide for Diabetic Macular Edema Completed NCT00369486 Phase 2 40mg triamcinolone;20mg triamcinolone;40mg triamcinolone + laser;20mg triamcinolone + laser
32 Treatment of Active Anterior Uveitis Associated With JIA, Using Humanized Anti-Tac (HAT, Daclizumab) Completed NCT00130637 Phase 2 Daclizumab
33 Pilot Study of Peribulbar Triamcinolone Acetonide for Diabetic Macular Edema Completed NCT00231023 Phase 2 Peribulbar Triamcinolone Acetonide
34 A Phase 2, Multi-Center, Randomized, Double-Masked, Active Controlled Study of ADVM-022 (AAV.7m8-aflibercept) in Subjects With Diabetic Macular Edema [INFINITY] Recruiting NCT04418427 Phase 2
35 Phase I/II Randomized, Prospective, Double-masked, Sham-controlled Study of Intravitreal Autologous Bone Marrow CD34+ Stem Cell Therapy for Central Retinal Vein Occlusion Recruiting NCT03981549 Phase 1, Phase 2
36 Intravitreal Bevacizumab Versus Intravitreal Triamcinolone Acetonide for Refractory Diabetic Macular Edema Unknown status NCT00468351 Phase 1
37 The Safety and Tolerability of Intravitreal Infliximab (Remicade) in Patients With Refractory Diabetic Macular Edema or Choroidal Neovascularization Secondary to Age Related Macular Degeneration- A Pilot Study Unknown status NCT00695682 Phase 1 intravitreal injection of infliximab
38 The Safety and Tolerability of Intravitreal Adalimumab in Patients With Refractory Diabetic Macular Retinopathy or Choroidal Neovascularization or Uveitis: A Pilot Study Unknown status NCT00855608 Phase 1 adalimumab
39 FVF3565s Intravitreal Ranibizumab (rhuFab V2) in the Treatment of Macular Edema Associated With Perfused Central (CRVO) Retinal Venous Occlusive Disease Completed NCT00406796 Phase 1 Ranibizumab
40 Phase I, Open-Label, Single-Center, Randomized, Study of the Safety and Efficacy of 0.5 mg and 2.0 mg Ranibizumab in Patients With Macular Edema Secondary to Perfused Central Retinal Vein Occlusion Completed NCT01028248 Phase 1 Ranibizumab (Lucentis)
41 Pilot Study of Intravitreal Injection of Triamcinolone Acetonide Formulation for Retinal Vascular Disorders Completed NCT00071227 Phase 1 Triamcinolone Acetonide (TAC-PF)
42 An Open Label, Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacodynamics of a Novel Intravitreal Plasma Kallikrein Inhibitor in Subjects With Central Involved Diabetic Macular Edema and Reduced Vision Completed NCT02193113 Phase 1 KVD001 Injection
43 Restoration of Retinal Vascular Responses in Type 1 Diabetic Patients Completed NCT02099981 Phase 1 Aminoguanidine
44 Pilot Study of Intravitreal Injection of Ranibizumab for Macular Telangiectasia Without Neovascularization (MACTEL 2) Completed NCT00685854 Phase 1 Ranibizumab
45 Pilot Study of Intravitreal Injection of Ranibizumab for Macular Telangiectasia With Neovascularization (MACTEL 1) Completed NCT00685503 Phase 1 Ranibizumab
46 Pilot Study of Intravitreal Injection of Ranibizumab for Macular Telangiectasia Without Neovascularization Completed NCT00457145 Phase 1 Ranibizumab
47 Pilot Study of Intravitreal Injection of Ranibizumab for Macular Telangiectasia With Neovascularization Completed NCT00457067 Phase 1 Ranibizumab
48 An Open-Label Phase Ib Study to Evaluate Retinal Imaging After Short-term Use of the Balance Goggles System (BGS) in Patients With Glaucoma Recruiting NCT04035239 Phase 1
49 A Pilot Clinical Trial of the Feasibility and Safety of Intravitreal Autologous Adult Bone Marrow Stem Cells in Treating Eyes With Vision Loss From Retinopathy Enrolling by invitation NCT01736059 Phase 1 CD34+ bone marrow stem cells intravitreal
50 An Open-label, Dose Escalating Study to Assess the Safety and Tolerability of a Single Administration of FOV2302 (Ecallantide) in Patients With Macular Edema Associated With Central Retinal Vein Occlusion Terminated NCT00969293 Phase 1 FOV2302 (Ecallantide)

Search NIH Clinical Center for Retinal Vascular Disease

Genetic Tests for Retinal Vascular Disease

Anatomical Context for Retinal Vascular Disease

MalaCards organs/tissues related to Retinal Vascular Disease:

40
Endothelial, Retina, Eye, Bone, Heart, Bone Marrow, Brain

Publications for Retinal Vascular Disease

Articles related to Retinal Vascular Disease:

(show top 50) (show all 4532)
# Title Authors PMID Year
1
Prolonged blockade of VEGF receptors does not damage retinal photoreceptors or ganglion cells. 61 54
20232317 2010
2
The effects of oxygen stresses on the development of features of severe retinopathy of prematurity: knowledge from the 50/10 OIR model. 61 54
19639355 2010
3
Non-arteritic anterior ischemic optic neuropathy (NA-AION) after intravitreal injection of bevacizumab (Avastin) for treatment of angoid streaks in pseudoxanthoma elasticum. 61 54
19916212 2009
4
Vascular endothelial growth factor-A: a multifunctional molecular player in diabetic retinopathy. 61 54
19646547 2009
5
Risk factors and growth factors in ROP. 54 61
19828269 2009
6
Blockade of angiotensin II attenuates VEGF-mediated blood-retinal barrier breakdown in diabetic retinopathy. 54 61
19107135 2009
7
Kallidinogenase normalizes retinal vasopermeability in streptozotocin-induced diabetic rats: potential roles of vascular endothelial growth factor and nitric oxide. 61 54
19374851 2009
8
Feedback mechanism between blood vessels and astrocytes in retinal vascular development. 61 54
19577710 2009
9
Association of vitreous inflammatory factors with diabetic macular edema. 61 54
19118698 2009
10
VEGF-induced choroidal damage in a murine model of retinal neovascularisation. 54 61
18523088 2008
11
Retinal vascular permeability suppression by topical application of a novel VEGFR2/Src kinase inhibitor in mice and rabbits. 54 61
18483622 2008
12
Aquaporin 1 is required for hypoxia-inducible angiogenesis in human retinal vascular endothelial cells. 61 54
18275976 2008
13
Vascular endothelial growth factor C promotes survival of retinal vascular endothelial cells via vascular endothelial growth factor receptor-2. 61 54
16943230 2007
14
Rebound macular edema following bevacizumab (Avastin) therapy for retinal venous occlusive disease. 61 54
17420693 2007
15
Molecular targets for retinal vascular diseases. 61 54
17133346 2007
16
Age-dependent retinal capillary pericyte degeneration in galactose-fed dogs. 61 54
17341153 2007
17
Retinopathy of prematurity. 61 54
17332988 2007
18
Reduction of experimental diabetic vascular leakage by delivery of angiostatin with a recombinant adeno-associated virus vector. 54 61
17293777 2007
19
Exogenous leukemia inhibitory factor (LIF) attenuates retinal vascularization reducing cell proliferation not apoptosis. 54 61
16643897 2006
20
Hepatocyte growth factor induces retinal vascular permeability via MAP-kinase and PI-3 kinase without altering retinal hemodynamics. 54 61
16723489 2006
21
Therapeutic potential of angiostatin in diabetic nephropathy. 54 61
16394111 2006
22
Role of the Norrie disease pseudoglioma gene in sprouting angiogenesis during development of the retinal vasculature. 54 61
16123442 2005
23
Predominant rod photoreceptor degeneration in Leber congenital amaurosis. 54 61
16052170 2005
24
Angiopoietin concentrations in diabetic retinopathy. 61 54
15774928 2005
25
Differential expression of connective tissue growth factor in microglia and pericytes in the human diabetic retina. 61 54
15258030 2004
26
VEGF isoforms and their expression after a single episode of hypoxia or repeated fluctuations between hyperoxia and hypoxia: relevance to clinical ROP. 54 61
15303088 2004
27
Pathogenesis of retinopathy of prematurity. 54 61
15135797 2004
28
VEGF and KDR gene expression during human embryonic and fetal eye development. 61 54
14691147 2004
29
An unusual retinal vascular morphology in connection with a novel AIPL1 mutation in Leber's congenital amaurosis. 61 54
12881340 2003
30
Inhibition of protein kinase C decreases prostaglandin-induced breakdown of the blood-retinal barrier. 54 61
12652648 2003
31
von Hippel-Lindau disease type 2A in a family with a duplicated 21-base-pair in-frame insertion mutation in the VHL gene. 61 54
12644949 2003
32
Pigment epithelium-derived factor expression in the developing mouse eye. 61 54
12447163 2002
33
Antioxidants attenuate early up regulation of retinal vascular endothelial growth factor in streptozotocin-diabetic rats. 61 54
11596663 2001
34
Role of VEGF-A in endothelial phenotypic shift in human diabetic retinopathy and VEGF-A-induced retinopathy in monkeys. 54 61
11340407 2001
35
Role of vascular endothelial growth factor in diabetic vascular complications. 54 61
10997700 2000
36
[Cell biology of intraocular vascular diseases]. 54 61
10643294 1999
37
VEGF increases retinal vascular ICAM-1 expression in vivo. 61 54
10393052 1999
38
Expression of vascular endothelial growth factor (VEGF) and its receptors is regulated in eyes with intra-ocular tumours. 54 61
10211121 1998
39
Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. 61 54
9287049 1997
40
Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the blood-retinal barrier in rabbits and primates. 54 61
9227268 1997
41
Upregulation of vascular endothelial growth factor in ischemic and non-ischemic human and experimental retinal disease. 61 54
9046048 1997
42
Vascular endothelial growth factor is present in glial cells of the retina and optic nerve of human subjects with nonproliferative diabetic retinopathy. 61 54
9008628 1997
43
Vascular endothelial growth factor--its role in retinal vascular proliferation. 54 61
7526213 1994
44
Oxidative stress induces adult T cell leukemia derived factor/thioredoxin in the rat retina. 61 54
8139268 1994
45
Electron microscopic immunocytochemical demonstration of blood-retinal barrier breakdown in human diabetics and its association with aldose reductase in retinal vascular endothelium and retinal pigment epithelium. 61 54
8226103 1993
46
Characterization of galactose-containing glycoconjugates in the human retina: a lectin histochemical study. 54 61
2091899 1990
47
Optical coherence tomography angiography findings in macular toxoplasma retinochoroiditis: A case report. 61
32551402 2020
48
Hyperreflective foci in diabetic macular edema with serous retinal detachment: association with dyslipidemia. 61
32114640 2020
49
Structure-function correlation of localized visual field defects and macular microvascular damage in primary open-angle glaucoma. 61
32240673 2020
50
Novel Detection and Restorative Levodopa Treatment for Preclinical Diabetic Retinopathy. 61
32051147 2020

Variations for Retinal Vascular Disease

Expression for Retinal Vascular Disease

Search GEO for disease gene expression data for Retinal Vascular Disease.

Pathways for Retinal Vascular Disease

Pathways related to Retinal Vascular Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.96 PLG MTHFR INS ALB
2 11.85 VEGFA MIR30A MIR21 MIR20A MIR126
3 11.47 MIR30A MIR20B MIR20A
4 11.15 VEGFA LIF KDR INS ALB
5 11.12 VEGFA PLG KDR
6
Show member pathways
10.96 VEGFA KDR INS

GO Terms for Retinal Vascular Disease

Cellular components related to Retinal Vascular Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.91 VEGFA SERPINF1 PLG NDP LIF KDR
2 extracellular space GO:0005615 9.5 VEGFA SERPINF1 PLG NDP MIR30A MIR21
3 extracellular vesicle GO:1903561 9.35 MIR30A MIR21 MIR20B MIR20A MIR126
4 platelet alpha granule lumen GO:0031093 9.33 VEGFA PLG ALB

Biological processes related to Retinal Vascular Disease according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 gene silencing by miRNA GO:0035195 10 MIR30A MIR21 MIR20B MIR20A MIR146B MIR126
2 positive regulation of cell proliferation GO:0008284 9.97 VEGFA MIR21 LIF KDR INS CCN2
3 positive regulation of gene expression GO:0010628 9.91 VEGFA MIR30A MIR21 LIF INS CCN2
4 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.88 MIR21 MIR126 KDR CCN2
5 positive regulation of protein phosphorylation GO:0001934 9.86 VEGFA MIR21 KDR CCN2
6 positive regulation of cell migration GO:0030335 9.8 VEGFA MIR30A MIR21 KDR INS
7 lung development GO:0030324 9.79 VEGFA LIF CCN2
8 positive regulation of MAPK cascade GO:0043410 9.76 MIR126 LIF KDR INS
9 positive regulation of endothelial cell migration GO:0010595 9.74 VEGFA MIR21 KDR
10 negative regulation of gene expression GO:0010629 9.73 VEGFA SERPINF1 MIR21 MIR20A KDR CCN2
11 positive regulation of cell migration involved in sprouting angiogenesis GO:0090050 9.69 VEGFA MIR126 KDR
12 cellular response to vascular endothelial growth factor stimulus GO:0035924 9.65 VEGFA MIR20A KDR
13 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.62 MIR21 MIR126 KDR INS
14 trophoblast giant cell differentiation GO:0060707 9.61 PLG LIF
15 positive regulation of positive chemotaxis GO:0050927 9.6 VEGFA KDR
16 negative regulation of cell-cell adhesion mediated by cadherin GO:2000048 9.59 VEGFA PLG
17 vascular wound healing GO:0061042 9.58 VEGFA KDR
18 negative regulation of apoptotic process GO:0043066 9.56 VEGFA MIR30A MIR21 KDR CRYAA ALB
19 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.55 VEGFA KDR
20 vascular endothelial growth factor receptor-2 signaling pathway GO:0036324 9.54 VEGFA KDR
21 positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903589 9.54 VEGFA MIR21 MIR126
22 positive regulation of blood vessel endothelial cell migration GO:0043536 9.46 VEGFA MIR30A MIR126 KDR
23 positive regulation of angiogenesis GO:0045766 9.1 VEGFA MIR30A MIR21 MIR20A MIR126 KDR

Molecular functions related to Retinal Vascular Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.1 MIR30A MIR21 MIR20B MIR20A MIR146B MIR126

Sources for Retinal Vascular Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....